a clinical-grade assay.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3259 Alzheimer's
on the ADNI site.—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=3448 Alzheimer's
to address these issues.—Esther Landhuis. This is Part 1 of a three-part series. See also Part 2, Part 3.
studies.—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=2630 Alzheimer's Disease Aβ
is going in, so we'll be that much more able to understand whether a drug is having an effect.”—Esther
treatment.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2303 Alzheimer's Disease Stem
Scientists don’t own their data.”—Esther Landhuis. This concludes our two-part series. See also Part 1. None
things, quite frankly. We've been looking at the ADAS-Cog for 15 years.”—Esther Landhuis. None
with the Clinical Trials on Alzheimer’s Disease Conference, 3-5 November 2011 in San Diego.—Esther Landhuis.
and assessing effects of therapy would be easier and quicker?” he wrote to Alzforum.—Esther Landhuis. None
on humans than simply the Aβ vaccine.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2617
of post-translational modifications and interacting proteins. For more on these developments, read Part 2.—Esther
cord express TMEM119 RNA, and the protein is highly restricted to microglia.—Esther Landhuis None
and join the discussion.—Esther Landhuis. Esther Landhuis is a science writer in Dublin, California.
of therapeutics more rapidly and effectively in future trials.”—Esther Landhuis. This is Part 1 of a two-part